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Effects of early and late antihypertensive treatment on extracellular
matrix proteins and mononuclear cells in uninephrectomized SHR. The
efficacy of an early and late treatment with the angiotensin converting
enzyme inhibitor lisinopril or the angiotensin II receptor blocker ICI
D8731 was investigated in uninephrectomized spontaneously hypertensive
rats (SHR). Rats that underwent uninephrectomy (UNX) at six weeks of
age were randomly assigned to receive no treatment, lisinopril shortly
after UNX, lisinopril starting 16 weeks after UNX, ICI D8731 shortly after
UNX, and ICI D8731 starting 16 weeks after UNX. Blood pressure was
normalized with both treatments. After six months inulin clearance was
not significant different, while proteinuria and prevalence of interstitial
fibrosis were significantly reduced in all treatment groups. Immunohisto-
chemical studies revealed an interstitial, periglomcrular and perivascular
increase of extracellular matrix proteins in all rats, but a markedly reduced
expression of collagen I, TV and fibronectin after early and late treatment
compared to untreated controls. We found a significant reduction of
infiltrating macrophages and T-lymphocytes in all treated animals com-
pared to untreated controls after 2, 4 and 6 months. Especially early
treatment was associated with lower numbers of infiltrating cells. Both
treatments reduced proliferation of tubular and interstitial cells. There
were no striking differences with regard to nephroprotection between the
ACE inhibitor and angiotensin II receptor blocker. These findings show
that both treatments have beneficial effects on kidney structure and
function. They suggest that both ACE inhibition and angiotensin II
blockade decrease renal cell proliferation and suppress the infiltration of
mononuclear cells that may trigger expression of extracellular matrix
proteins and progressive nephrosclerosis.
The uninephrectomized spontaneously hypertensive rat (UNX
SHR) is a model of severe hypertension and progressive kidney
damage [1]. The UNX SHR and other hypertensive rat models
are similar in that antihypertensive drugs can reduce renal injury.
Based upon other studies it has been suggested that drugs
influencing the renin-angiotensin system may be superior to other
agents in their ability to protect the kidney. However, it is not
clear if blocking of angiotensin II (Ang II) receptors or inhibition
of angiotensin converting enzyme (ACE) is more effective in
preventing progressive nephrosclerosis 12].
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In previous studies we have shown in two-kidney, one-clip rats
that hypertension leads to an early tubular cell proliferation,
mononuclear cell recruitment, and deposition of matrix proteins
primarily within the interstitium [3]. These data indicate that the
injury triggering nephrosclerosis extends far beyond the glomeruli
to both the tubules and the interstitium. In contrast to two-kidney,
one clip (2K1C) rats nephrosclerosis of UNX SHR develops over
months and is more appropriate to the human renal disease,
which usually advances slowly over many years.
In the present study, we compared the effect of long-term
administration of an Ang II type I receptor antagonist with that of
an ACE inhibitor in UNX SHR. To evaluate the efficacy of a
treatment that starts after a 16 weeks period of hypertensive renal
injury, we compared these rats both with untreated controls and
rats receiving an antihypertensive treatment shortly after unine-
phrectomy.
Studies on hypertensive nephrosclerosis, which is one of the
most frequent causes of end-stage renal failure [4], have focused
on hypertensive damage to glomeruli [5]. However, interstitial
fibrosis may be an even more important determinant of renal
injury [6—81. It is generally accepted that interstitial changes,
including cellular infiltration and fibrosis, correlate better with
clinical parameters of progression than do glomerular changes
[9—111. To gain more insight into these mechanisms we performed
a series of long-term intervention studies and focused on cellular
proliferation, extracellular matrix deposition and mononuclear
cell infiltration in correlation to histological and functional
changes.
Methods
Description of groups
Studies were performed in five groups of SHR which underwent
right nephrectomy at six weeks of age. We used 11 groups each
with 8 rats for light microscopy and immunhistochemistry studies
(24 rats were sacrificed after S and 16 weeks, respectively, 40 rats
were sacrificed after 24 weeks) and an additional five groups with
6 rats for inulin clearance determinations after 24 weeks (118 rats
total). Control (CON) rats were fed standard rat chow (Altromin,
Lage, Germany) and given tap water to drink. LIS rats were fed
identical chow and were given the ACE-inhibitor lisinopril orally
750
Geiger et al: Antihypertensive treatment in UNX SHR 751
(5 mg/kg/day) by gastric gavage in the morning once a day. In
LIS-E rats treatment with the ACE inhibitor was started shortly
after UNX had been performed. LIS-L rats received lisinopril
starting 16 weeks after UNX. D87 rats were given D8731 daily by
gastric gavage. D8731 is a new angiotensin II antagonist charac-
terized by blocking angiotensin II type I receptors (synthesized by
ICI Pharmaceuticals, Mereside, UK, and kindly provided by Dr.
Low, ZENECA GmbH, Plankstadt, Germany). In pilot studies
different dosages of lisinopril and D8731 were tested to maintain
systolic blood pressure below 140 mmm Hg. In the protocol we
used 20 mg/kg/day of D8731. We began application of D8731
shortly after UNX in D87-E rats and 16 weeks after UNX in
D87-L rats.
Design of the long-term study
Animals were placed in metabolic cages and a 24-hour urinary
protein excretion was determined after six months. Systolic blood
pressure was measured at four week intervals under light ether
anesthesia by using tail-cuff plethysmography. For each rat, the
value recorded represented the mean of four to six measurements
obtained at a single sitting. Blood parameters (urea, creatinin,
renin activity) and body wt and kidney weight were measured after
six months.
Twenty-four weeks after UNX, the rats were anesthetized with
mactin (100 mg/kg, i.p.). A tracheostomy was performed and the
animals were fixed on a warmed experimental table (Medax;
Nagel KG, Kiel, Germany) which secured a constant body tem-
perature (controlled by rectal digital temperature measurements).
Polyethylene catheters were inserted into the femoral artery and
vein. Arterial pressure was measured by a Statham pressure
transducer (Sensotec Inc., CA, USA) connected to a pressure
recorder (Recomed; FA. Hellige, Freiburg, Germany). The uri-
nary bladder was punctured supraphyseal and cannulated with a
polyethylen catheter (ID 0.5 mm, OD 1.0 mm). To compensate
for surgical losses and specimens drawn, all rats received an
intravenous infusion of Ringer's solution (Fa. Fresenius, Bad
Homburg, Germany) 10 ml/kg body wt at a rate of 0.1 mI/mm.
Then the rats were given an intravenous infusion of 50 jsl/min
FITC-inulin. After a 45-minute equilibration period, two timed
urine collections of fifteen minutes each were made. At the
midpoint of each collection, 100 tl blood was collected in
microtubes.
Morphologic studies
For light microscopy, one half of each kidney was fixed in 4%
buffered törmalin and embedded in paraffin. Four-micrometer-
thick sections were stained with the periodic acid-Schiff reagent,
hematoxylin and cosin, van Gieson's elastica, and the movat silver
technique. All histological studies were performed without knowl-
edge of the regimes or their duration (blinded). The interstitial
volume was estimated by morphometric methods by means of a
point-counting technique as described by Weibet [12] and Ben-
nett, Walker and Kincaid-Smith [131. Sections were examined
with a 100-point grid fitted in the eyepiece of the microscope.
Twenty consecutive high-power fields (x400) were counted in all
cases to evaluate the extent of the interstitial fibrosis.
Matrix molecules
The immunofluorescence of the matrix proteins, collagen I and
IV, and flhronectin was examined after renal tissue was snap-
frozen in isopentane, precooled in liquid nitrogen, and stored at
—70°C. Five-micrometer-thick cryostat sections were placed on
chromalaun/gelatin-coated slides, air-dried, and processed by an
indirect immunofluorescence technique to detect the matrix com-
ponents.
After preincubation with 100% fetal calf serum (FCS) for 30
minutes, the sections were consecutively covered with the specific
primary polyclonal antibodies diluted in phosphate-buffered sa-
line (PBS) containing 1% bovine serum albumin (BSA) for one
hour, and with a secondary fluorescein-isothiocyanate-conjugated
immunoglobulin (Ig) G [sheep anti-rabbit F(ab)2 fragment (1:10,
Boehringer Mannheim, Germany) or donkey anti-goat IgG (1:40,
Dianova, Germany)] diluted in PBS containing 1% BSA and 1%
FCS for 60 minutes. The incubations were carried out at 37°C
temperature in a humid chamber. Each of these steps was
preceded by three washes in PBS for five minutes. The sections
were mounted in buffered moviol/gelatin and examined with a
Leitz fluorescent microscope.
To assess matrix accumulation, we compared the immunofluo-
rescence staining of kidneys from the US and D87 with another
and with those from the control group. A semiquantitative
estimate reflected changes in the area of matrix staining rather
than intensity. The sections were independently graded by three
observers who were unaware (blinded) of the regimes.
Mononuclear infiltration
For immunohistochemical staining of mononuclear cell infiltra-
lion, 5-sm-thick cryostat sections were fixed 10 minutes in cold
acetone, air-dried, immersed in Tris-buffered saline (TBS, pI-I
7.4), and preincubated with 100% FCS for 30 minutes at 37°C
temperature. Monoclonal anti-ED1 or anti-CD4 antibodies di-
luted in 1% BSA/TBS were applied for 60 minutes at 37°C
temperature. After washing with TBS (3 times for 5 mm), the
sections were incubated with rabbit anti-mouse immunoglobulin,
and the immunoreactivity was visualized by alkaline phosphatase—
anti-alkaline-phosphatase (APAAP) method (Dakopatts, Ger-
many) as proposed by the manufacturer using the neufuchsin
substrate kit (Dakopatts) for detection. The endogenous alkaline
phosphatase is blocked by an addition of levamisole (Sigma,
Germany) at an end concentration of 10 mmol/liter to the
substrate solution. The sections were light counterstained in
hematoxylin for 10 seconds (Gill No. 3, Sigma), blued in running
tap water (10 mm) and mounted with aquatex (Merck, Germany).
The quantitation of the tubulointerstitial infiltration was deter-
mined by selecting cortical areas at random. Large blood vessels
and glomeruli were avoided. The numbers of ED1+ and CD4+
cells were counted in 20 high-power sections (X250 and X400) by
means of a 1 cm2 grid fitted into the eyepiece of the microscope.
The mean values are expressed as cells per millimeter squared
SEM. The mean numbers of ED1+ and CD4+ cells per glomerular
cross section were determined by evaluating 60 glomeruli in each
renal SectiOn.
Cell proliferation
The immunostaining for proliferating cell nuclear antigen
(PCNA) was carried out on methyl Carnoy's fixed and paraffin-
embedded tissues. Briefly, the sections (4-j.tm thick) were depar-
affinized in xylene and a graded series of ethanols and rehydraded
three times for three minutes in PBS (containing 0.01% Triton
X-100 plus 0.1% BSA). The sections were then covered with the
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Table 1. Organ weights and renal biochemical parameters
Weight Kidney weight Blood pressure
mm Hg
PRA
mglml*hr
Urea Creatinine GFR
mi/mm
.Proteinuria
mg/daymg/dlGroup g
CON 320 5 2.00 0.06 170 4 5.5 1.7 38.4 2.1 0.36 0.01 1.67 0.15 32.9 4.9
LIS-L 320 8 1.90 0.04 125 3" 24.6 4.3" 48.8 2.1" 0.34 0.02 1.72 0.21 18.2 6.1"
D87-L 310 7 1.98 0.04 120 5" 18.4 4.0" 47.1 2.6" 0.32 0.02 1.64 0.07 14.0 3.7"
LIS-E 310 7 1.87 0.04 115 5" 18.2 1.7" 51.8 31" 0.41 0.02 1.85 0.38 10.0 3.5"
D87-E 310 5 1.96 0.05 120 6" 22.4 0.6" 50.7 2.3" 0.36 0.03 2.05 0.23 18.7 1.4
Abbreviations are: PRA, plasma renin activity; CON, control rats; LIS-E, rats fed lisinopril starting after uninephrectomy; D87-E, rats fed D8731
starting after uninephrectomy; LIS-L, rats fed lisinopril starting 16 weeks after uninephrectomy; D87-L, rats fed D8731 starting 16 weeks after
uninephrectomy.
a P < 0.05 vs. CON
primary monoclonal PCNA (PC1O) antibody diluted in PBS
overnight at 4°C in a humid chamber, washed with PBS (0.01%
Triton X-100 plus 0.1% BSA), and subsequently processed using
diaminobenzidine (DAB) (Dakopatts).
Different PCNA staining patterns are believed to reflect indi-
vidual phases of the cell cycle. The distinct and intense 2+ and 3+
nuclear staining identifies cells in the S phase [14]. The cell
proliferation was quantified as follows. We counted only cells with
intense, deep red 3+ nuclear staining. The mean number of
proliferating cells in the tuhulointerstitium was determined by
counting the PCNA+ cells in 30 fields per tissue section at a
magnification of x250. A 1 cm2 grid was used for this purpose that
was fitted to the eyepiece of the microscope and large blood
vessels ignored. The glomerular PCNA+ cells were counted
separately by sequentially examining 90 glomeruli in each kidney
section.
Analytical techniques
Protein in urine was measured by the biuret method. For
plasma renin activity (PRA) determinations, the blood collected
into prechilled (4°C) polypropylene tubes, which contained a
solution of 5% 125 mtvi EDTA. After centrifugation (6000 g, 10
mm at 4°C) plasma was stored at —20°C until assay. PRA was
determined by measuring the Ang I generation by radioimmuno-
assay [151.
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Fig. 1. Systolic blood pressure Line graphs show time course of systolic blood
pressure (mean SEM). All treated rats remain normotcnsive while
controls develop hypertension. "P < 0.01 (comparison between treated
and untreated rats), p < 0.01 (comparison between US and D87), °P <
0.01 (comparison between LIS-E and LIS-L). Symbols are: (A) CON; (S)
LIS; (•) D87; (•) LIS-L; (V) D87-L.
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Fig. 2. Protein excretion rates in uninephrectomized SHR groups are defined
in text. "P < 0.05 versus CON.
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Fig. 3. Glomerular filtration rate determined as inulin clearance. There
were no significant differences between treated and untreated rats 24
weeks after uninephrectomy.
The following polyclonal and monoclonal antibodies were used:
collagen 1, rabbit anti-rat antiserum (1:10; Pasteur Diagnostika,
Germany); collagen IV, purified rabbit anti-mouse IgG (1:200;
Collaborative Research Inc., Bedford, MA, USA); fibronectin,
goat anti-human lgG (1:1000; gift from Dr. S. Goodman, MPI,
Erlangen, Germany); ED1, (1:1000; Serotec, Germany), a murine
monoclonal anti-rat IgG to a cytoplasmatic antigen present in
macrophages, monocytes, and dendritic cells; W3/25, (1:2000;
Serotec), a murine monoclonal anti-rat lgG to surface CD4
antigen on T lymphocyte helper cells; and PC1O (1:100; Dianova,
Germany), a murine monoclonal lgG against recombinant rat
PCNA [16]. The proliferating cell nuclear antigen PCNA/cyclin is
a highly conserved 36 kDa auxiliary protein of DNA polymerase
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Fig. 4. Photomicrographs show renal morphology in experimental rats. In rats with early treatment interstitial fibrosis was not found 24 weeks after UNX
(A; arrows represent not thickened arterioles), in contrast to untreated control rats (C), in which fibrosis (arrowheads) with infiltrates of mononuclear
cells was accentuated near the iuxtaglomerular region and around disinctly thickened arterioles (arrows). The smaller extent of interstitial fibrosis
(arrowheads) in rats with late antihypertensive treatment 24 weeks after UNX (B) corresponded well with untreated animals after 16 weeks (i; arrows
point to slightly thickened arterioles). In contrast to the almost unchanged glomeruli in rats with early antihypertensive treatment 24 weeks after UNX
(D), an augmentation of mesangial matrix as one of the criteria benign nephrosclerosis was seen in untreated rats after 24 weeks (F) and less pronounced
in rats with late treatment (E). Additionally, an increased thickening of the walls of arteries and arterioles has developed in controls after 16 weeks (G)
and 24 weeks (H) with obliterative vascular changes. In rats with late treatment, vascular lesions seemed to be less distinct after 24 weeks compared to
untreated controls after 16 weeks (I; arrows are arterioles). A, LIS-E/24w; B, LIS-L/24w; C, CON/24w; D, D87-E/24w; E, D87-L/24w; F, CON/24w; G,
CON/24w; H, CON724w; I, CON/16w (A-C, H&E, X200; D-I, H&E, ><320).
delta. Synthesis of this protein begins in the late Gi phase and
peaks during the S phase, followed by a decrease in G2IM phase
of the cell cycle. Negative controls consisted of substitution of the
primary antibody with both equivalent concentrations of an
irrelevant murine monoclonal antibody or normal rabbit IgO and
PBS.
Statistics
Data are reported as the mean SEM. The data were examined
by one-way analysis of variance (ANOVA) and two-tailed un-
paired Students f-test with Bonferoni's correction. Statistical
significance was defined as P < 0.05. To correlate interstitial
volume with blood pressure and PRA, we used the Spearman's
rank correlation coefficient.
Results
Weight and biochemical parameters
Body and organ weights, serum urea and creatinine, PRA, and
a similar amount of weight from time of nephrectomy to time of
sacrifice. Protein intake of the rats should be similar because the
protein content of the diets were identical. Final weights in the
five groups averaged 310 and 320 g and were not significantly
different, Different treatments did not affect kidney weight signif-
icantly compared to controls.
Twenty-four weeks after nephrectomy serum urea was signifi-
cantly (P < 0.01) elevated in US and D87 groups compared to
untreated controls. In contrast, serum creatinine was not different
between the groups. Plasma renin activity turned out to he
significantly (P < 0.001) elevated in rats with ACE-inhibitor or
Ang II receptor blocker, indicating a positive feedback mecha-
nism. We found no significant differences of plasma renin activi-
ties between rats receiving lisinopril or D87. Measurements of
urine sodium, potassium and calcium showed decreased values in
lisinopril treated rats (P < 0.01), both with an early and a late
application of the drug. Urine osmolality was not significantly
Rats in all groups had free access to food and water and gained
proteinuria are summarized in Table 1. changed between all groups.
hypertensive rats (P < 0.00 1). Early antihypertensive treatment
prevented the expansion of interstitial volume almost completely
(LIS-E, 8.6 0.1%/8 weeks, 9.3 0.4%/24 weeks; D87-E, 8.7
0.1%18 weeks, 9.2 0.2%124 weeks; P < 0.001). When antihy-
pertensive treatment was started 16 weeks after UNX the progre-
dient increase of interstitial volume could be stopped (Lis-L,
10.6 0.4%/24 weeks; and D87-L, 11.0 0.5%/24 weeks vs.
CON, 13.4 0.6%/24 weeks; P < 0.01) but did not reverse the
established interstitial volume expansion (CON, 11.2 0.3%1l6
weeks; NS).
Time, weeks
Fig. 5. Expansion of interstitial volume Results of morphometric evaluation
of interstitial area. *p < 0.01 (comparison between treated and untreated
rats), p < 0.01 (comparison between early and late treatment). There
was no significant difference between late treated rats (24 weeks) and
control rats (16 weeks). Symbols are: (•) CON; (•) US; ([A) D87; (X)
LIS-L; (*) D87-L.
Blood pressure
As summarized in Figure 1, systolic hypertension was present in
untreated SHR by the time of the initial systolic pressure deter-
mination four weeks after nephrectomy. The rats never developed
blood pressure values above 200 mm Hg at any time. Beginning
antihypertensive treatment immediately after nephrectomy, blood
pressure remained normotensive over the entire time indepen-
dently of the drug choice. When antihypertensive treatment was
started 16 weeks after UNX, blood pressure was normalized both
with lisinopril and with D87.
Proteinuria and renal function
Both lisinopril (18.2 6.1 and 10.0 3.5 mg/day) and D87
(14.0 3.7 and 18.7 1.4 mg/day) reduced proteinuria signifi-
cantly (P < 0.01) compared to controls (32.9 4.9 mg/day; Fig.
2). Glomerular filtration rate measured as inulin clearance (Fig.
3) showed no significant difference (control, 1.67 0.15 ml/min;
LIS-L, 1.72 0.21 mI/mm; D87-L, 1.64 0.07 mi/mm; Lis-E,
1.85 0.38 ml/min; D87-E, 2.05 0.23 ml/min).
Morphological studies
Eight weeks after UNX we found no glomerular or arteriolar
morphologic changes that could be described as characteristic for
hypertensive renal damage. Sixteen and, more pronounced, 24
weeks after UNX, control rats showed signs of benign nephro-
sclerosis (thickening of the arterial wall, moderate degree of
arteriolar hyalinosis) but we did not observe fibrinoid necrosis of
arterioles, onion skins or reduplication of the internal elasic
lamina. Glomeruli were characterized by moderate increase of
cells and matrix expansion, but there were no distinct focally
sclerotic lesions. Interstitial fibrosis was largely expressed in the
juxtaglomerular region. Expansion of interstitial fibosis in un-
treated rats 16 weeks after UNX was equivalent with the findings
in rats with the late treatment 24 weeks after UNX. With
antihypertensive treatment, thickening of the vessel walls seemed
to be less pronounced and marked glomerular lesions were not
delectable (Fig. 4),
Figure 5 illustrates the progressive interstitial expansion from
8.8 0.1% to 13.4 0.6% after six months in untreated
Extracellular matrix proteins
Hypertension-induced changes in extracellular matrix mole-
cules have been reported in detail in previous studies [31.The
semiquantitative evaluation of the matrix proteins revealed a
progressive accumulation of collagens I and IV and fibronectin.
The most consistent changes were observed primarily in the renal
interstitium, periglomerular and perivascular locations. Here a
mild, focal accumulation of collagens I and IV and fibronectin was
already detectable eight weeks after UNX. Rats treated early with
lisinopril or D87 were characterized by a clear-cut lower expres-
sion of matrix proteins, and differences between control and
treated animals became more evident after 16 weeks. At 24 weeks
the accumulation of collagens and fibronectin were generalized
and paralleled the expansion of extracellular volume. In contrast,
the weak staining pattern of the glomerular matrix remained
nearly unchanged during the first 16 weeks, and showed a mild to
moderate increase after 24 weeks. The immunhistochemical stud-
ies in LIS-L and D87-L rats revealed a reduced interstitial
expression of collagens I and IV and fibronectin 24 weeks after
UNX compared to controls at 16 weeks, but the reduction of
matrix proteins was not as extensive as in early treated rats (Table
2). We found no striking differences between the ACE inhibitor
and the angiotensin II receptor blocker. Representative examples
are shown in Figure 6).
Mononuclear cell infiltration
Elevated blood pressure and progression of interstitial volume
was associated with a significant increase in interstitial infiltration
by T helper cells in controls (Fig. 7A). The values for CD4+ cells
were 185 9 cells/mm2 (8 weeks) and 324 25 cells/mm2 (24
weeks; P < 0.001). We found a significant reduction of infiltrating
T helper cells in all treated animals compared to untreated
controls after two, four and six months. Twenty-four weeks after
UNX, interstitial accumulation of CD4+ cells was significantly
lower (P < 0.01) in rats that were treated early (LIS-E, 128 3
cells/mm2 vs. US-U, 159 6 cells/mm2; D87-E, 152 6 cells/mm2
vs. D87-L, 184 10 cells/mm2) and in LIS-E rats compared to
D87-E rats (P < 0.01). The difference between the two drug
regimens could not be confirmed for the late starting treatment.
We found a significant reduction of T helper cells with late
treatment after 24 weeks compared with untreated controls at 16
weeks (268 26 cells/mm2; P < 0.01).
A significant interstitial increase of influx of macrophages was
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Table 2. Immunhistochemistry of interstitial extracellular matrix proteins
Collagen I Collagen IV Fibronectin
8 weeks 16 weeks 24 weeks 8 weeks 16 weeks 24 weeks 8 weeks 16 weeks 24 weeks
Con ++ +++ ++++ ++ +++ ++++ ++ +++ ++++
LIS-E + + + + + + + + +
D87-E + + + + + + + + +
LIS-L — ++ — — ++ — — ++
D87-L — — ++ — — ++ — — ++
Semiquantitative evaluation is: (+) mild increase, (++) moderate increase, (+++) marked increase, (++++) severe increase.
A Collagen I Collagen IV Fibronectin
Fig. 6. Immunofluorescence staining of matrix proteins. (A) Vertical axis shows hypertensive controls after 8 and 24 weeks and histologic sections of
normotensive rats after 24 weeks (early treatment with ACE-inhibitor). Horizontal axis shows collagen I and IV and fibronectin. There is a markedly
reduced interstitial, perivascular and periglomerular expression of extracellular matrix proteins with antihypertensive treatment. (B) Vertical axis shows
hypertensive controls at 16 weeks and rats with late treatment at 24 weeks. Top: collagen 1, middle: collagen IV, bottom: fibronectin.
also observed in untreated controls after 24 weeks (CON 8 weeks,
37 4 cells/mm2; CON 16 weeks, 33 3 cells/mm2; CON 24
weeks, 58 7 cells/mm2; P < 0.01). Both early and late treatment
reduced the influx of macrophages significantly (P < 0.001)
compared to controls, and early treatment was significantly (P <
0.01) more effective at the end point of the experiment (LIS-E,
19 5 cells/mm2 vs. LIS-L, 30 3 cells/mm2; D87-E, 24 I
cells/mm2 vs. D87-L, 31 1 cells/mm2; Fig. 7B). The number of
macrophages was not different between late treatment at 24 weeks
compared with untreated controls at 16 weeks. There were no
differences between the ACE inhibitor and Ang II receptor
blocker treatment in reducing influx of macrophages.
Cell proliferation
Cell proliferation was quantitated by immunostaining tissue
sections for PCNA, a nuclear protein that is increased from the
late G1 to the M phases of the cell cycle. No increase of
proliferating cells was observed from weeks 8 to 16 after UNX
(CON/8, 31 6 cells/mm2; CON/16, 22 5 cells/mm2; LIS/8,
27 4 cells/mm2; LIS/16, 28 4 cells/mm2; D87/8, 25 4
cells/mm2; D87/16, 12 2 cells/mm2), but there was a significant
CON 8W
CON 24 W
LIS-E 24 W
-'
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Collagen I
Collagen IV
Fibronectin
CON 16W LIS-L24W
Fig. 6. Continued.
(P < 0.001) elevation of PCNA+ cells in untreated rats 24 weeks
after UNX (56 15 cells/mm2). In contrast to hypertensive
control rats, PCNA+ cells did not increase in normotensive rats
after 24 weeks both with early (LIS-E, 25 7 cells/mm2; D87-E,
28 4 cells/mm2) and with late treatment (LIS-L, 28 7
cells/mm2; D87-L, 22 4 cells/mm2). The difference to controls
was highly significant (P < 0.001).
Discriminating between the tubular PCNA+ and interstitial
PCNA+ cells, no differences were found among the various drug
treatments, but there was a significant (P < 0.001) divergence to
hypertensive controls at the end of the study time (CON/tub, 29 8
cells/mm2; CON/int, 25 9 cells/mm2; LIS-E/tuh, 11 2 cells/mm2;
LTS-E/int, 14 6 cells/mm2; D87-E/tub, 11 2 cells/mm2;
D87-E/int, 16 3 cells/mm2; LIS-L/tub, 13 3 cells/mm2;
LIS-L/int, 13 5 cells/mm2; D87-L/tub, 9 2 cells/mm2; D87-L/
int, 10 2 cells/mm2). We found no significant differences with
late treatment after 24 weeks and untreated controls at 16 weeks
(CON/tub, 11 2 cells/mm2; CON/int, 9 3 cells/mm2). In
contrast, glomeruli sporadically showed only single PCNA+ cells.
The results of PCNA+ staining of tubular and interstitial cells are
shown in Figure 8.
Discussion
In many diseases of the kidneys the progression to end-stage
renal failure depends largely on the severity of the injury to the
tubulointerstitial compartment [10]. Extensive reduction of renal
mass is one of several possibilities of inducing glomerulosclerosis
and interstitial fibrosis in the rat. Also, many rat strains develop
glomerulosclerosis spontaneously and there is a wide variety in
susceptibility, which suggests a dependency upon the genetic
backround [17]. The spontaneously hypertensive rat is a model of
severe system hypertension and nephrosclerosis, in the course of
B
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Fig. 7. Quantitation of mononuclear cell
infiltration. Groups are defined in text. *p <
CON [IS D87 CON US 087 CON LIS- 087- US- 087- 0.01. A. Interstitial T helper cells (CD4+). B.
8 8 8 16 16 16 24 E 24 E 24 L24 L 24 Interstitial macrophages (ED1+).
which renal fibrosis is more progressive if renal ablation is
performed at an early age.
In previous studies a renoprotective effect of ACE inhibitors
has been proven in uninephrectomized Wistar rats [181 and
uninephrectomized SHR [1] when ACE inhibitor treatment was
started early, from the moment of nephrectomy. In contrast to this
prophylactic drug regimen, only few data arc available on treat-
ment modalities with a late onset of antihypertensive treatment in
these rats, which would resemble most conditions in humans. An
important question in the pharmacology of renin-angiotensin
inhibition is whether angiotensin II antagonists and ACE inhibi-
tion have identical effects or whether they can be differentiated.
For that reason, in addition to the investigation of an early and a
late onset of therapy, ACE inhibition of angiotensin converting
enzyme was compared with the more specific blocking of the
angiotensin II receptor type I (AT1).
In our study, uninephrectomized SHR developed nephroscle-
rosis with the progressive expansion of interstitial volume, accu-
mulation of fibronectin and collagens I and IV in the renal
interstitium, perivascular and periglomerular increase of T-helper
cells and macrophages, and a rise of proliferating tubular and
interstitial cells. Treatment with the ACE inhibitor lisinopril or
with the AT1-blocker D8731 had a favorable effect on intrarenal
lesions. Administration of the two drugs was beneficial if therapy
was started immediately after renal ablation, and even after a time
delay when fibrotic lesions were evident. Both drugs reduced
proteinuria, interstitial volume and fibrosis, expression of extra-
cellular matrix components, the number of infiltrating mononu-
clear cells, and decreased proliferating tubular and interstitial
cells. Light microscopy evaluations demonstrated very clearly that
a retarded initiation of treatment can only prevent further injury
but does not reverse established renal lesions in this model. We
found only a slightly lower level of extracellular matrix proteins
and a significant reduction of interstitial T helper cells with late
treatment after 24 weeks compared with untreated controls at 16
weeks. 1he number of macrophages and proliferating cells was
not different between late treated rats and untreated controls at
the time point beginning the late drug therapy. In this model of
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Fig. 8. Analysis of cell proliferation. Bar graphs
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0 (PCNA+ cells) at total (A) and at tubular (B)
CON [IS D87 CON [IS 087 CON [IS- D87- [IS- 087- and interstitial (C) sites (mean SEM). Groups
8 8 8 16 16 16 24 E24 E24 L24 L24 are defined in text. *J) < 0.01.
uninephrectomized SHR we could not find a significant in- phase of tubulointerstitial injury. In contrast to this, both
crease of cell proliferation after 16 weeks, indicating that cell tubular and interstitial PCNA positive cells were significantly
proliferation is not an important determinant in this early elevated after 24 weeks. This observation corresponds with
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findings in 2KIC hypertensive rats where the increase of
proliferating cells has been documented in the late phase of
renal injury [3].
Intraglomerular hypertension and hyperfiltration, such as that
induced by a reduction of renal mass, have been discussed as
important hemodynamic factors in the progression of glomerular
injury. Dworkin et a! [1] reported elevated glomerular capillary
pressure in uninephrectomized SHR that was reduced by enala-
pril. They proposed that this hemodynamic effect of the ACE-
inhibitor was responsible for preventing progressive kidney dam-
age. In a micropuncture study of rats with five-sixths renal
ablation Baboolal and Meyer [19] could not demonstrate any
effect of angiotensin II blockade with losartan on glomerular
pressure. Since age-dependent glomerular injury can apparently
occur without concomitant glomerular hypertension [20], the
protective effect of ACE inhibitors [21] may be independent of
any influence on GC Ichikawa and Harris point to the different
effects of ACE inhibition or angiotensin II blocking on glomerular
pressure either when the drugs were chronically (reduction) or
acutely (no change) administrated [22]. Although several mecha-
nisms have been proposed as underlying the protective action of
the ACE inhibitor, the elimination of the renal effect of Ang II is
considered the principal mechanism. This notion is supported by
recent data of Crary et a! [23], who demonstrated that in a setting
of chronic renal damage where intrarenal RAS activity does not
appear to be increased, angiotensin II receptor antagonism may
not be nephroprotective despite a reduction in blood pressure.
Other discussed mechanisms for the renoprotective effect of ACE
inhibitors are decrease of mesangial traffic or macromolecules,
stimulation of NO synthesis by bradykinin, as well as reduction of
mesangial proliferation directly or by decreasing PDGF [24]. The
latter effect would explain the beneficial effect observed with ACE
inhibitors in glomerulopathies in which glomerular capillary pres-
sure is not elevated [25].
Angiotensin II has been demonstrated to increase the expres-
sion of collagen types I and IV in renal cells in vitro [26, 27] and
indirectly in a high renin model in vivo [3]. Recently, Panizo et a!
proved that treatment of spontaneously hypertensive rats with the
ACE inhibitor quinapril decreased myocardial accumulation of
collagen fibers and reduced the expression of collagen IV, fi-
bronectin and laminin [28]. In addition, Kim et a! showed that the
AT1 antagonist TVC-116, despite no reduction of blood pressure,
decreased renal mRNA levels for collagens I, II and IV and
fibronectin in stroke-prone spontaneously hypertensive rats [29].
In our study we found a markedly reduced expression of collagens
I and IV and fibronectin both with the ACE inhibitor and with the
AT1 blocker. Remarkably, even a late treatment reduced expres-
sion of these extracellular matrix components. These data are in
good agreement with those of Kakinuma et at, who demonstrated
a favorable effect of treatment with ACE inhibitors or Ang II
receptor antagonist on intrarenal lesions when treatment was
started eight weeks after renal ablation [30].
In various experimental models of chronic renal failure, ACE
inhibition produced a comparable renoprotective effect as does
AT1 receptor blocking, both in renal ablation models [3 1—33] and
in spontaneously hypertension [34]. In contrast, in rats with
puromycin aminonucleoside nephrosis [35] or with passive Hey-
mann nephritis [36] proteinuria was strikingly attenuated by ACE
inhibition, but was unaffected by an angiotensin II receptor
antagonist. Theoretically, angiotensin II blockade could provide a
more complete blockade of angiotensin II than ACE inhibitors.
However, ACE inhibitors may have additional actions apart from
the inhibition of angiotensin II production. Differences between
the two drug classes in their clinical effects could also be based on
the fact that after blockade of AT1 receptors, Ang II levels
increase manyfold, possibly overstimulating the unblocked, un-
protected AT2 receptor [37].
Kidneys exposed to high pressures are infiltrated by macro-
phages and T helper cells [3, 38], which may secrete a large
number of vasoactive substances, cytokines, and growth factors
[39]. It is known that interstitial morphological changes correlate
well with declining renal function while glomerular changes do
not [40]. In contrast to the glomerular leukocyte infiltrate, which
is composed primarily of macrophages, the interstitial leukocyte
infiltrate contains approximately equal numbers of T cells and
macrophages [41]. In the present study we found a significant
increase of interstitial infiltration of T helper cells and macro-
phages in untreated rats with predominating T helper cell counts.
Both early and late treatment with the ACE inhibitor and with the
AT1 receptor antagonist reduced the number of mononuclear
cells. Early treatment was significantly more effective in reducing
infiltrating cells. Previous investigations have strengthened the
argument that in several diseases with tubulointerstitial injury the
number of interstitial mononuclear cells is important, which
correlates both with the degree of renal dysfunction and the risk
for progression [42, 43]. Our data suggest that the ACE inhibitor
and AT1 receptor blocker suppress interstitial infiltration of
mononuclear cells in uninephrectomized SHR, by which they may
attenuate progressive nephrosclerosis.
A tubulointerstitial fibrogenic effect of angiotensin II has been
demonstrated in vitro and in vivo [44]. Infusion of angiotensin II
stimulates the proliferation of distal and collecting tubular cells
[45]. This mitogenic effect could be mediated by the angiotensin II
receptors on tubular cells [46]. Studies of the tubulointerstitial
scarring process give evidence that angiotensin II has the potential
of activating tubular and interstitial renal cells to produce extra-
cellular matrix proteins. Data from this study demonstrate that
treatment with the ACE inhibitor or with the AT1 receptor
blocker significantly reduces proliferating tubular and interstitial
cells. The decreased number of proliferating cells was not only
achieved with the early treatment but also with the late starting
regimen. These results show that onset of therapy in those with
advanced renal disease may reverse deleterious pathogenetic
mechanisms.
This study cannot answer the question of how inhibition of
angiotensin II reduces renal interstitial scarring. One possibility
would be the favorable influence on angiotensin II and tubular-
derived growth factors and cytokines [47]. Another explanation
could be the increase of ammoniagenesis of proximal tubular cells
by angiotensin II [48—50]. High levels of ammonia may promote
tubular and interstitial injury by activating the alternative comple-
ment cascade [51].
In summary, compelling arguments have been made for the
therapeutic relevance of the renin-angiotensin system both in
clinical and experimental hypertension. The present study pro-
vides evidence that not only early treatment but also a late onset
of therapy may ameliorate hypertension-induced nephrosclerosis.
Our results in uniriephrectomized SHR demonstrate that treat-
ment with an ACE inhibitor or with an AT1 receptor blocker
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decreases extracellular matrix proteins and renal cell prolifera-
tion, and suppresses the interstitial infiltration of T helper cells
and macrophages that may trigger a cascade of events resulting in
nephrosclerosis. There were no striking differences with regard to
nephroprotection between the ACE inhibitor and angiotensin II
blocker. Whether angiotensin II receptor antagonists are as
renoprotective in humans as ACE inhibitors cannot yet be an-
swered [52].
Further studies are required to characterize the mechanisms
leading to interstitial nephrosclerosis and to elucidate the role of
monuclear cells in this process.
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